CD274 and neoplasm: The ingenuity of the concept resides in substituting the inhibitory signaling structural domain of PD-1 with the activating signaling structural domain of 4-1BB while retaining the external structural domain of PD-1 responsible for binding to PD-L1 on tumor cells.